Vical plummets on placebo promise in herpes study
This article was originally published in Scrip
Executive Summary
San Diego-based Vical's stock was cut almost in half on 23 June after the company reported that the placebo in a Phase I/II clinical trial outperformed both the monovalent and bivalent forms of its therapeutic genital herpes vaccine by a wide margin. In terms of the trial's primary endpoint, viral shedding decreased 12% for patients treated with the monovalent vaccine, 19% in the study's bivalent arm and 45% in the placebo group.
You may also be interested in...
Vical Faced With Failure of Another Vaccine Trial
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.